RCKT - ROCKET PHARMACEUTICALS, INC.
IEX Last Trade
11.905
-0.160 -1.344%
Share volume: 128,324
Last Updated: Thu 26 Dec 2024 08:30:11 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$12.06
-0.16
-1.33%
Fundamental analysis
9%
Profitability
8%
Dept financing
6%
Liquidity
50%
Performance
0%
Performance
5 Days
2.19%
1 Month
-17.22%
3 Months
-33.64%
6 Months
-45.14%
1 Year
-62.55%
2 Year
-33.71%
Key data
Stock price
$11.90
DAY RANGE
$11.32 - $12.11
52 WEEK RANGE
$11.61 - $31.47
52 WEEK CHANGE
-$62.20
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/04/2024
Company detail
CEO: Gaurav D. Shah
Region: US
Website: rocketpharma.com
Employees: 240
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: rocketpharma.com
Employees: 240
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Rocket Pharmaceuticals, Inc. focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells. The company also has a clinical stage in vitro virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure.
Recent news